undamentalytics Newsletter
Sign in

Solventum revenue

Solventum's revenue was $8.32bn in fiscal 2025, up 0.9% on the year before. Since fiscal 2022 ($8.13bn) it has grown at a compound 0.8% a year. Over the last twelve months it was $8.31bn.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8,1308,1978,2548,3258,310
Growth on the year before—+0.8%+0.7%+0.9%—
Gross profit4,6954,6934,5934,4514,545
Gross margin57.7%57.3%55.6%53.5%54.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $6.3B 76.3% 0.0%
Cost of Software and Rentals $2B 23.7% ▲ 3.7%
Geography
Region Revenue Share YoY
United States $4.7B 56.1% ▲ 2.4%
Outside the US $3.7B 43.9% ▼ 1.0%

From Solventum's 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Technology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Solventum $8.31bn -0.9% —
Veeva Systems Inc $3.46bn 16.5% 15.7%
Teladoc Health, Inc. $2.47bn -2.4% -1.5%
Tempus AI, Inc. $1.51bn 36.6% —
Waystar Holding Corp. $1.26bn 21.4% —
Omnicell, Inc. $1.25bn 8.5% 0.3%

Compare with peers

Head to head: SOLV vs VEEVSOLV vs TDOCSOLV vs TEM

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Solventum's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Solventum.